Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Whole exome sequencing can assist in early diagnosis of various disorders

Whole exome sequencing can assist in early diagnosis of various disorders

Approximately one-fourth of the 3,386 patients whose DNA was submitted for clinical whole exome testing received a diagnosis related to a known genetic disease, often ending a long search for answers for them and their parents, said researchers from the Baylor College of Medicine departments of molecular and human genetics and pediatrics and the Baylor Human Genome Sequencing Center and the University of Texas Health Science Center at Houston. [More]
Low vitamin D levels linked to poor brain function after sudden cardiac arrest

Low vitamin D levels linked to poor brain function after sudden cardiac arrest

Vitamin D deficiency increases the risk of poor brain function after sudden cardiac arrest by seven-fold, according to research presented at Acute Cardiovascular Care 2014 by Dr Jin Wi from Korea. Vitamin D deficiency also led to a higher chance of dying after sudden cardiac arrest. [More]
Genome Canada awards $6M grant to CAMH and Assurex Health

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. [More]
Longer Looks: An Alabama Judge's Dismantling Of Roe V. Wade; The Mystery Of Enterovirus; Mutating Ebola

Longer Looks: An Alabama Judge's Dismantling Of Roe V. Wade; The Mystery Of Enterovirus; Mutating Ebola

In the nine years Parker has now served on the court, he has made the most of his opportunities. Child custody disputes, for instance, have made good occasions to expound on the role of religion in parental rights. [More]
Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. [More]
Cell transplantation treatment may benefit people with spinal cord injury

Cell transplantation treatment may benefit people with spinal cord injury

Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies. [More]
New combination therapy shows promise in treating prostate cancer

New combination therapy shows promise in treating prostate cancer

Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness. [More]
Highland completes US$25 million offering of Class A Common Shares

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success. [More]
MGH, MIT partner to accelerate development of diagnostic tools and therapies

MGH, MIT partner to accelerate development of diagnostic tools and therapies

A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies. [More]
Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

Treeway and LACDR at the University of Leiden join forces and form a collaboration focused on the optimization of clinical trial designs and data-analysis for ALS (Amyotrophic Lateral Sclerosis) through the use of population disease progression models. [More]
New oncology trial management functionality now added into Clinical Conductor CTMS

New oncology trial management functionality now added into Clinical Conductor CTMS

The team behind Clinical Conductor is proud to announce brand new enhancements to the industry-leading CTMS. This first oncology focused release of several in the coming quarters adds a multitude of advanced features and functionalities designed to optimize the management and execution of oncology studies at organizations of all sizes and makeups. [More]
NeuroSigma, VA partner to evaluate eTNS system for TBI patients in Phase I clinical trial

NeuroSigma, VA partner to evaluate eTNS system for TBI patients in Phase I clinical trial

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial. [More]
Broccoli sprout compound may help ease classic behavioral symptoms in people with autism

Broccoli sprout compound may help ease classic behavioral symptoms in people with autism

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs). [More]
Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

The Mount Sinai Hospital is first in the United States to use the first and only FDA-approved, drug-coated balloon to open blocked arteries in the leg. [More]
Discovery could prolong life of people living with glioblastoma

Discovery could prolong life of people living with glioblastoma

Researchers at the University of Calgary's Hotchkiss Brain Institute and Southern Alberta Cancer Research Institute have made a discovery that could prolong the life of people living with glioblastoma – the most aggressive type of brain cancer. Samuel Weiss, PhD, Professor and Director of the HBI, and Research Assistant Professor Artee Luchman, PhD, and colleagues, published their work today in Clinical Cancer Research, which is leading researchers to start a human phase I/II clinical trial as early as Spring 2015. [More]
Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. [More]
Research opens door to potential new treatments for peripheral artery disease

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness. [More]
C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland. [More]
Pharmaceutical industry withdraws from the antibiotic space

Pharmaceutical industry withdraws from the antibiotic space

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive. [More]
Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor, with various factors stacking the odds against successful treatment: early detection is uncommon, it tends to spread quickly and recurrence is likely. However, several newer approaches show promise in increasing the response rate to pancreatic cancer treatment. [More]